Pain in palliative care: A review

Pharmaceutical Journal

Volumn 278, Issue 7455, 2007, Pages 679-682

  Dickman, Andrew ^a  

^a Cardiothoracic Center   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBAMAZEPINE; CELECOXIB; CLONAZEPAM; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; DICLOFENAC; ETODOLAC; GABAPENTIN; IBUPROFEN; LUMIRACOXIB; MELOXICAM; MORPHINE; NAPROXEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARACETAMOL PLUS TRAMADOL; PHENYTOIN; PROTON PUMP INHIBITOR; ROFECOXIB; SCOPOLAMINE BUTYL BROMIDE; TRAMACET; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB; WARFARIN;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; BLOOD DISEASE; BONE PAIN; CANCER PAIN; CANCER PALLIATIVE THERAPY; CARDIOVASCULAR DISEASE; CHRONIC PAIN; CLINICAL TRIAL; COLIC; COUNSELING; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG DOSE TITRATION; DRUG WITHDRAWAL; DYSPEPSIA; FEAR; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; KIDNEY DISEASE; LOW DRUG DOSE; MONOTHERAPY; MUSCULOSKELETAL PAIN; NAUSEA; NEPHROTOXICITY; NEUROPATHIC PAIN; NOCICEPTION; PHYSICAL STRESS; RECOMMENDED DRUG DOSE; REVIEW; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TRANSCUTANEOUS NERVE STIMULATION; VISCERAL PAIN; VOMITING;

EID: 34250736347     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Melzack R, Wall PD. Pain mechanisms: a new theory. Science 1965; 150:971-9.
2. Melzack R. Evolution of the neuromatrix theory of pain. Pain Practice 2005;5:85-94.
3. Zech DFJ, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organisation guidelines for cancer pain relief: a 10-year prospective study. Pain 1995;63:65-76.
4. McNicol E, Strassels SA, Goudas L, Lau J, Carr DB. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. The Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No: CD005180.
5. Dickman A, Ellershaw J. NSAlDs: gastroprotection or selective COX-2 inhibitor? Palliative Medicine 2004; 18:275-86.
6. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chomoprevention trial. New England Journal of Medicine 2005; 352: 1092-102.
7. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrano C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8.
8. Langman MJS, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 3434:1075-8.
9. Nielsen OH, Ainsworth M, Csillag C, Rask-Madsen J. Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients? Alimentary Pharmacology & Therapeutics 2006; 23:27-33.
10. Lazzaroni M, Bianchi Porro G. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Alimentary Pharmacology & Therapeutics 2004;20 (Suppl. 2): 48-58.